Before finalizing the first-ever ADA/EASD Consensus Report on the management of adults with type 1 diabetes, the writing team led by Anne L. Peters, MD, and Richard I.G. Holt, PhD, FRCP, highlighted key topics addressed in the report at the Scientific Sessions.

Kristen J. Nadeau, MD, MS, outlined the unique cardiometabolic mechanisms and consequences of youth-onset type 1 and type 2 diabetes in her award lecture.

An infectious disease epidemiologist, a journalist, and a researcher—Christina M. Astley, MD, ScD, Gary Schwitzer, and Bertha Hidalgo, PhD, MPH—came together to share their perspectives on communication of risk and its impact on public health and public trust.

An international panel of diabetes prevention researchers including Mike Sampson, MD, Kerri Lynn Knippen, PhD, MPH, RDN, LD, BC-ADM, Pilvikki Absetz, PhD, and Anne M. Wolf, MS, RDN, shared lessons learned from the implementation of type 2 diabetes prevention programs around the world during a symposium Monday.

“We know there are so many people who are getting suboptimal care in terms of diabetes—inpatient and outpatient—because we can’t reach them all. We really need to use technology as a base,” said Amisha Wallia, MD, MS.

The story of incretins began in the gut—and then something happened, said Jens Juul Holst, MD, DrMedSci. Islets and the pancreas developed from the gut and remain connected by gut hormones, he noted.

As an early-career scientist, Nicholas J. Wareham, FMedSci, FRCP, FFPHM, MBBS, MSc, PhD, developed a strong interest in diabetes screening and was fascinated by then-emerging details of the links between risk factors and type 2 diabetes.

“One of the lessons from the discovery of insulin is to remind us how important it is for us to support high-risk innovative ideas, new and junior investigators—in addition to more established investigators—and basic, clinical, and translational research,” said ADA President, Medicine & Science, Ruth S. Weinstock, MD, PhD.

“The central nervous system is an important target organ for GLP-1 and GIP pharmacotherapy to affect energy balance,” said Alice Adriaenssens, PhD, in the ADA Diabetes Symposium.

David G. Marrero, PhD, advocated for a social-ecological model to better understand and integrate diabetes care in a symposium focused on preserving mental health across the lifespan of living with this disease.